Pharmacolog has received a patent approval from the American Patent Office for adaptive drug treatment. The patent strengthens the already registered patent, US 2018/0028750 A, which was approved February 2018.
In 2018, the US Patent Authority approved the Company’s patent application for the method and system for dose regulation of the drug concentration in the infusion during treatment. In connection with the approval, the authority offered the opportunity to submit a new so-called divisional patent application which widens the requirement list and further specifies which constituent regulatory parameters affect the dose regulation. The patent now covers dose regulation from physiological and biological response parameters such as temperature, breathing, biomarkers in various body fluids. The new application has now been approved by the American Patent Office and is valid until 2035.
Hans Dahlin, Founder and Head of Research commented, “This is a major advance that strengthens our patent situation for new future products within Personalized Medicine. The two US patents provide strong protection for our future solutions in adaptive drug treatment. In order to be able to offer real individualized care, one also needs to change the way in which one is currently medicating. An effective treatment of severely ill patients requires continuous consideration of the patient’s reactions.”
Pharmacolog is specialized in developing systems and solutions for more effective and safer use of intravenous drugs. The company’s first product, DrugLog®, enables a nurse or pharmacist to quickly and easily verify that an injectable drug has the right identity and concentration. Pharmacolog’s long-term vision is an individually optimized medication for each individual patient, considering all available parameters in the control and distribution of the drug. Further information regarding the company is available at http://www.pharmacolog.com. The company’s Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.